Applied Therapeutics Inc. (NASDAQ: APLT) is a clinical-stage biopharmaceutical company developing innovative treatments for rare and life-threatening diseases. Its research focuses on small-molecule therapies targeting metabolic and neurological disorders, with key drug candidates like AT-007 for galactosemia and AT-001 for diabetic cardiomyopathy. By leveraging cutting-edge science, the company aims to address high-unmet-need conditions with precision medicine. Since its founding in 2016, Applied Therapeutics has been advancing novel therapies to improve patient outcomes.